Lilly's approved cancer drug Lartruvo fails confirmatory study, setting the stage for withdrawal of regulatory endorsement
Back in 2016, Lilly won FDA accelerated approval for its soft tissue drug olaratumab on the basis of encouraging data from a small 133 …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
